コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 fibres, with examples including serpins and cystatins.
3 le protein with tetratricopeptide repeats 1, cystatin 1, and interferon-inducible protein with tetrat
4 tion is incompatible with previous models of cystatin amyloid fibrils where the beta-sheet is assumed
5 including Tenascins, Cathepsin-B precursor, cystatin, and numerous Variant-specific Surface Proteins
6 ion, and intracellular content of all type 2 cystatins as well as expression and activity of their po
7 and three were successfully verified, namely cystatin B (CSTB), triosephosphate isomerase (TPI1), and
8 y form of cerebral amyloid angiopathy whilst cystatin B aggregates are found in cases of Unverricht-L
13 of lipid accumulation in TgCRND8 by removing cystatin B inhibition on lysosomal proteases suggests th
15 m ROS was attenuated in an NPC cell model by cystatin B over-expression or pharmacological inhibition
18 ied the effects of diminishing expression of cystatin B, an endogenous inhibitor of cathepsins B, H a
21 at least partially parallel, arrangement for cystatin beta-sheet structure in mature amyloids and pro
22 y C-reactive protein greater than 3.0 mg/dL, cystatin C >/=1.11 mg/dL, estimated glomerular filtratio
24 rs911119 was associated with decreased serum cystatin C (6.13% per allele; 95% CI: 5.75 to 6.50; p =
25 l relative risk for CVD of 1.00 per doubling cystatin C (95% CI: 0.82 to 1.22; p = 0.994), which was
26 alysis, we examined the relationship between cystatin C (a marker of renal function) and PASP and pot
29 tion rate (GFR) equations incorporating both cystatin C (CysC) and serum creatinine (Creat) in living
32 t renal function measures are imperfect, and cystatin C (CysC) is promoted as a better marker of glom
35 ed GFR estimated from creatinine (eGFR(Cr)), cystatin C (eGFR(Cys)), or both (eGFR(Cr+Cys)) with ioth
38 GFR should be calculated and reported using cystatin C (eGFRcys) and serum creatinine (eGFRcr-cys) o
39 d GFR estimated from creatinine (eGFRcreat), cystatin C (eGFRcys), and both (eGFRcreat-cys) at baseli
40 dominant disorder in which a variant form of cystatin C (L68Q) readily forms amyloid deposits in cere
41 imilarly, both in patients with high and low cystatin C (median cut-off), higher plasma NGAL levels w
42 le risk prediction model, eGFR (P=0.616) and cystatin C (P=0.937) were no longer associated with mort
43 8.30-21.2); Pnoninferiority = 0.0011], serum cystatin C (Pnoninferiority < 0.0001), serum creatinine
44 n decline of eGFR (Ptrend<0.001) and rise of cystatin C (Ptrend=0.01) and creatinine (Ptrend<0.001) l
46 bining a functional damage biomarker (plasma cystatin C [pCysC]) with a tubular damage biomarker (uri
48 , we developed estimating equations based on cystatin C alone and in combination with creatinine in d
50 lculated by the measurement of creatinine or cystatin C alone or in combination with creatinine, with
56 howed increased levels and distinct forms of cystatin C amyloid that were not present in WT mice.
58 L68Q epididymal fluid that was depleted of cystatin C amyloids, however, did not impair the motilit
59 cohorts (n = 76,481) with 37,126 measures of cystatin C and added genetic data from 43 studies (n = 2
62 ult ICU survivors, we compared ICU discharge cystatin C and creatinine and their association with 1-y
67 highly ordered, domain-swapped assemblies of cystatin C and that the oligomers could not build larger
68 Here we aimed to investigate if uptake of cystatin C and the related inhibitor cystatin E/M occur
69 Conversely, lower creatinine relative to cystatin C appeared to confer adverse prognosis, confoun
70 herapeutics targeted at lowering circulating cystatin C are unlikely to be effective in preventing CV
71 implications for the diagnostic use of serum cystatin C as a marker of kidney function during inflamm
74 red childhood kidney volumes, creatinine and cystatin C blood levels, microalbuminuria, BP, and eGFR.
77 ss than 60 mL/min/1.73 m when estimated from cystatin C compared with glomerular filtration rate esti
78 baseline and 0- to 24-week changes in plasma cystatin C concentration with measures of vascular disea
81 ation rate (eGFR) using serum creatinine and cystatin C concentrations, and microalbuminuria using ur
85 These could be used to selectively remove cystatin C dimers from biological fluids containing both
86 diagnostic performance of CKD-EPI creatinine-cystatin C equation (2012) in patients with cirrhosis wa
87 Performance of the new CKD-EPI creatinine-cystatin C equation (2012) was superior to previous crea
89 ubjects, GFR estimated by CKD-EPI creatinine-cystatin C equation differed from the mGFR by more than
90 te the performance of the CKD-EPI creatinine-cystatin C equation in subjects with cirrhosis, we compa
92 and "accuracy" of the new CKD-EPI creatinine-cystatin C equation to that of 24-hour urinary creatinin
94 ongestion end point) and the change in serum cystatin C from enrollment to 72 hours (renal function e
97 from serum concentrations of creatinine and cystatin C has been refined using cross-sectional data f
98 ne the extent to which the addition of serum cystatin C improves glomerular filtration rate (GFR) est
99 vation and inflammation were associated with cystatin C in a multivariable model independent of creat
100 l variable to investigate the causal role of cystatin C in CVD, including coronary heart disease, isc
104 ile serum creatinine fell at 12 hours, serum cystatin C increased, suggestive of decreased creatinine
105 prostate cancer cells corroborated that the cystatin C internalization is generally relevant and con
106 iological studies show that high circulating cystatin C is associated with risk of cardiovascular dis
107 ndelian randomization to investigate whether cystatin C is causally related to CVD in the general pop
112 he extracellular concentration of inhibitory cystatin C is thus partly dependent on the abundance of
113 714 to 1171 mL; P = .59) or on the change in cystatin C level (dopamine, 0.12 mg/L; 95% CI, 0.06-0.18
114 618 to 1176 mL; P = .49) or on the change in cystatin C level (nesiritide, 0.07 mg/L; 95% CI, 0.01-0.
115 ely associated with childhood creatinine and cystatin C levels (all P values <0.05), but did not asso
119 ated on the basis of creatinine (eGFRcr) and cystatin C levels were assessed in </=1735 participants
121 After adjustment for both creatinine and cystatin C levels, higher discharge creatinine was then
122 easured GFR from standardized creatinine and cystatin C levels, sex, and age in the learning sample;
124 munodeficiency virus (HIV) infection, plasma cystatin C may be influenced by factors other than glome
125 C, and elution from columns with immobilized cystatin C oligomers, oligomer-specific antibodies were
128 ons, little is known about the regulation of cystatin C production, dimerization, and secretion.
129 of cystatin C under the control of the mouse cystatin C promoter were unable to generate offspring, s
131 ation coefficient, serum creatinine-to-serum cystatin C ratio was found to be the best performer in t
135 ss or diet), or interference with the assay, cystatin C should be measured and estimated GFR should b
137 , these results suggest that the addition of cystatin C to creatinine to estimate GFR may improve ide
139 L68Q) that express the human L68Q variant of cystatin C under the control of the mouse cystatin C pro
141 hereditary cystatin C amyloid angiopathy, a cystatin C variant is deposited in arterial walls and ca
143 ne eGFR was 54+/-20 mL/min per 1.73 m2, mean cystatin C was 11.2 (7.7-16.2) mg/L, and median plasma N
148 ysis adjusted for age, sex, and comorbidity, cystatin C was near-linearly associated with increased m
152 ge glomerular filtration rate estimated from cystatin C well matched follow-up chronic kidney disease
153 mated glomerular filtration rate (eGFR), and cystatin C were assessed in 562 patients with heart fail
159 ration equation, the eGFR was estimated from cystatin C with all available samples per participant ex
160 extent comparable with the W106F variant of cystatin C with optimal uptake properties and resulting
162 ed vesicular co-localization of internalized cystatin C with the lysosomal marker proteins cathepsin
163 the legumain binding region (N39K- and N39A-cystatin C) decreased the internalization and (R24A,R25A
164 L9G,V10G)-, (R8G,L9G,V10G,W106G)-, and W106G-cystatin C) were internalized to a very low extent compa
165 binding protein, urinary interleukin-18, and cystatin C) were measured in 1,635 unselected emergency
169 ct to limits of detection (CRP, 0.10 mug/mL; cystatin C, 0.003 mug/mL) and coefficients of variation
170 he extracellular cysteine protease inhibitor cystatin C, 12 variants of the protein were produced and
172 al serum potassium levels and measurement of cystatin C, a non-creatinine measure of kidney function.
174 immunosorption, using immobilized monomeric cystatin C, and elution from columns with immobilized cy
175 Four markers (albumin, beta-2-microglobulin, cystatin C, and osteopontin) were undetectable in most A
176 isease Epidemiology Collaboration creatinine-cystatin C, and urate and high-sensitivity C-reactive pr
177 with increased aortic pulsed wave velocity, cystatin C, and urinary albumin-to-creatinine ratio.
178 fication improvement with the measurement of cystatin C, as compared with creatinine, was 0.23 (95% c
179 FR to a higher value with the measurement of cystatin C, as compared with creatinine, was associated
182 s, and of the potential legumain inhibitors, cystatin C, E/M, and F, cystatin C was the one mainly pr
185 of GFR-estimating equations with and without cystatin C, including the modification of diet in renal
187 allel with Elmo1, as do the plasma levels of cystatin C, lipid peroxides, and TGFbeta1, and erythrocy
188 ed GFR, the formula with both creatinine and cystatin C, namely, CKD-epidemiology cr-cys, outperforme
190 lternative biomarkers (haematocrit, cTnI-hs, cystatin C, or creatinine clearance) also outperformed t
191 not increase albuminuria, proteinuria, serum cystatin C, or serum creatinine levels in TxNIP(-/-) mic
192 plasma biomarkers of renal injury including Cystatin C, Osteopontin, Tissue Inhibitor of Metalloprot
197 ation, we use redox experiments of monomeric cystatin C, stabilized against domain swapping by an int
198 atients had lower levels of cardiotrophin-1, cystatin C, syndecan-4, and N terminal-probrain natriure
200 neutrophil gelatinase-associated lipocalin, cystatin C, trefoil factor 3, tissue inhibitor of metall
202 eded in a number of assays, such as that for cystatin C, where a 1.5-fold increase in concentration m
203 id not provide evidence for a causal role of cystatin C, with a causal relative risk for CVD of 1.00
204 terminal pro-B-type natriuretic peptide, and cystatin C, with longer QRS interval, with lower heart r
206 ecreased the internalization and (R24A,R25A)-cystatin C, with substitutions of charged residues not i
207 mination of renal function by creatinine and cystatin C-based eGFR revealed decreasing eGFRs in the d
208 (2) of body-surface area was higher with the cystatin C-based eGFR than with the creatinine-based eGF
210 tly associated with childhood kidney volume, cystatin C-based eGFR, or the risk of microalbuminuria.
217 lable creatinine at baseline (n=17 951), and cystatin C-based glomerular filtration rate was estimate
218 our knowledge, no previous studies have used cystatin C-based measures of the estimated glomerular fi
219 IS1: creatinine-based; BIS2: creatinine- and cystatin C-based) with other estimating equations and de
220 0% (creatinine-based) and approximately 50% (cystatin c-based), indicating that 90% of the estimation
221 1 promotes fibrosis by driving the effective cystatin C-dependent inhibition of extracellular matrix-
222 ) in young and middle-aged adults who have a cystatin C-derived estimated glomerular filtration rate
223 D) in children, such as creatinine level and cystatin C-derived estimated glomerular filtration rate
241 omarkers (haemoglobin, cTn-hs, and GDF-15 or cystatin C/CKD-EPI) was internally and externally valida
242 factors (relative risk: 1.82 per doubling of cystatin C; 95% confidence interval [CI]: 1.56 to 2.13;
244 tive protein, urinary albumin excretion, and cystatin-C had similar risk for new-onset HF between bot
246 -treated groups had a 35% reduction in serum cystatin-C levels and reduced crescent numbers compared
247 n factor 15), GAL-3 (galectin-3), and Cys-C (cystatin-C) were assessed before TAVR and in 100 sex-mat
248 y cardiac troponin T), renal (creatinine and cystatin-C), and hepatic (aspartate transaminase and ala
249 sC5b-9) and renal injury markers (clusterin, cystatin-C, beta2-microglobulin, and liver fatty acid bi
250 , galectin-3, midregional proadrenomedullin, cystatin-C, interleukin-6, procalcitonin, and others.
252 We further assessed the impact of using cystatin-C-based eGFR in risk prediction equations for C
253 and international guidelines recommend that cystatin-C-based estimates of GFR be used to confirm or
257 he control group; Chromogranin-A[rs9658644], Cystatin-C[rs2424577] and Vitamin K-Dependent Protein S[
259 ts indicated that a gene encoding a putative cystatin (CC9) is induced upon penetration by U. maydis
261 m tuberosum) multicystatin (PMC) is a unique cystatin composed of eight repeating units, each capable
262 sistently, transcriptomic analysis show that cystatin D alters gene expression, including that of gen
264 ese results support an unanticipated role of cystatin D in the cell nucleus, controlling the transcri
266 Here, we demonstrate that a proportion of cystatin D locates within the cell nucleus at specific t
267 hermore, using cytokine arrays we found that cystatin D reduces the secretion of several protumor cyt
268 ied 292 proteins differentially expressed in cystatin D-expressing cells involved in cell adhesion, c
269 of the crystalline form but also exposure of cystatin domains for inhibition of cysteine proteases.
270 verse relationship between the expression of cystatin E/M and cathepsin L and a direct relationship b
272 nd a direct relationship between the loss of cystatin E/M expression and nuclear expression of NF-kap
276 or alpha (TNF-alpha), confirming the role of cystatin E/M in the regulation of the NF-kappaB signalin
277 take of cystatin C and the related inhibitor cystatin E/M occur in melanoma cell lines and to evaluat
284 nd medical applications of several sugarcane cystatins, including CaneCPI-1, CaneCPI-2, CaneCPI-3, an
286 ts in the industrial process of lysozyme and cystatin isolation from egg white, and (ii) evaluate the
287 , determined at 1.93 A resolution, shows the cystatin-like fold and is highly similar to the structur
288 lecular interaction site on HRG, possesses a cystatin-like fold composed of a 5-stranded antiparallel
292 Under conditions that favour fibrillisation, cystatins populate stable 3D domain-swapped dimers both
293 dundant cathepsins, inhibited by Ca074Me and cystatins, promote pro-IL-1beta synthesis, and to our kn
295 etic non-antibody capture protein based on a cystatin scaffold that displays high affinity for human
296 Specifically, acidic proline-rich protein, cystatin, statherin and protein S100-A9 proteins compete
298 lation of intracellular enzyme activity by a cystatin variant selected from uptake properties was ill
300 e derived from ovalbumin, ovotransferrin and cystatin were isolated from the most active fractions.
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。